$-0.40 EPS Expected for InflaRx N.V. (IFRX); Shorts at DNA DYNAMICS (DNAD) Lowered By 36.71%




August 5, 2018 – By Theresa McIntyre

Analysts expect InflaRx N.V. (NASDAQ:IFRX) to report $-0.40 EPS on August, 16.After having $-0.49 EPS previously, InflaRx N.V.’s analysts see -18.37% EPS growth. The stock decreased 5.91% or $1.98 during the last trading session, reaching $31.52. About 13,558 shares traded. InflaRx N.V. (NASDAQ:IFRX) has 0.00% since August 5, 2017 and is . It has underperformed by 12.57% the S&P500. Some Historical IFRX News: 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa

DNA DYNAMICS INC (OTCMKTS:DNAD) had a decrease of 36.71% in short interest. DNAD’s SI was 70,700 shares in August as released by FINRA. Its down 36.71% from 111,700 shares previously. The stock increased 12.12% or $0.0004 during the last trading session, reaching $0.0037. About 2.11M shares traded. DNA Dynamics, Inc. (OTCMKTS:DNAD) has 0.00% since August 5, 2017 and is . It has underperformed by 12.57% the S&P500.

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. The company has market cap of $808.87 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Schaeffersresearch.com which released: “3 Healthcare Stocks Making Massive Moves” on July 13, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on July 13, 2018, Streetinsider.com published: “BMO Capital Starts Inflarx NV (IFRX) at Outperform” on July 13, 2018. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Benzinga.com and their article: “30 Stocks Moving In Friday’s Mid-Day Session” published on July 13, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Top Upgrades, Downgrades For July 13, 2018” with publication date: July 13, 2018.

DNA Dynamics, Inc., through its subsidiaries, develops mobile applications and games for smartphones and tablet devices. The company has market cap of $. It develops and publishes games for Apple iPhone/iPad/iPod touch and Android platforms; and develops video games and applications for mobile devices and handheld consoles. It currently has negative earnings. The firm develops games across seven platforms, including titles for TV brands and intellectual property holders.

InflaRx N.V. (NASDAQ:IFRX) Ratings Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *